港股异动丨君实生物(01877.HK)逆势拉升近4% 与礼来合作研发及商业化君实新冠抗体
格隆汇5月4日丨君实生物(01877.HK)逆势拉升,由跌转升至近4%,报38.85港元,高见39.9港元再创历史新高,总市值达304.6亿港元。君实生物今早发布公告称,近日,公司与美国礼来制药公司签署了《研发合作和许可协议》。根据协议,双方将合作研发及商业化SARS-CoV-2中和抗体(“君实新冠抗体”,产品代号:JS016),并且,礼来制药将被授予在大中华地区(包括中国大陆、香港地区、澳门地区及台湾地区)外对君实新冠抗体开展研发活动、生产和销售的独占许可。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.